Bulletin
Investor Alert

New York Markets Open in:

Market Snapshot Analyst Ratings

GW Pharmaceuticals PLC ADR

NAS: GWPH

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
GW Pharmaceuticals PLC ADR

After Hours

 --Quotes are delayed by 20 min

Mar 2, 2021, 6:15 p.m.

GWPH
/zigman2/quotes/209686240/composite

$

214.75

Change

-0.14 -0.07%

Volume

Volume 328

Quotes are delayed by 20 min

/zigman2/quotes/209686240/composite

Previous close

$ 214.91

$ 214.89

Change

-0.02 -0.0093%

Day low

Day high

$214.71

$215.22

Open

52 week low

52 week high

$67.98

$217.50

Open
Income Statement Balance Sheet Cash Flow Statement

Annual Financials for GW Pharmaceuticals PLC ADR

View Ratios
Fiscal year is January-December. All values USD millions. 20162017201820192020 5-year trend
Sales/Revenue 14.58M10.58M15.49M312.62M531.31M
Cost of Goods Sold (COGS) incl. D&A 9.03M11.64M11.01M27.31M37.82M
COGS excluding D&A 3.84M4.55M1.63M18.03M24.97M
Depreciation & Amortization Expense 5.18M7.09M9.38M9.28M12.86M
Depreciation 5.1M6.78M8.49M8.03M-
Amortization of Intangibles 87,661314,865892,8881.25M-
Gross Income 5.56M(1.06M)4.48M285.31M493.48M
20162017201820192020 5-year trend
SG&A Expense 164.13M188.8M278.63M408.23M545.65M
Research & Development 141.13M142.87M133.49M147.28M206.99M
Other SG&A 23.01M45.93M145.14M260.96M338.66M
Other Operating Expense -----
Unusual Expense -536,177---
EBIT after Unusual Expense -(536,177)---
Non Operating Income/Expense 36.13M(6.48M)(2.13M)102.27M(4M)
Non-Operating Interest Income 859,6392.08M8.91M8.5M1.83M
Equity in Affiliates (Pretax) -----
Interest Expense 244,601956,6681.26M1.09M1.13M
Gross Interest Expense 244,601956,6681.26M1.09M1.13M
Interest Capitalized -----
Pretax Income (121.84M)(195.76M)(268.62M)(13.25M)(55.47M)
Income Tax (31.83M)(26.61M)4.07M(4.19M)3.11M
Income Tax - Current Domestic -2.15M4.06M--
Income Tax - Current Foreign 1.66M--9.55M-
Income Tax - Deferred Domestic (2.82M)(3.2M)8,785--
Income Tax - Deferred Foreign ---(9.74M)-
Income Tax Credits 30.68M25.56M-4.01M-
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income (90M)(169.15M)(272.69M)(9.06M)(58.58M)
Minority Interest Expense -----
Net Income (90M)(169.15M)(272.69M)(9.06M)(58.58M)
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries (90M)(169.15M)(272.69M)(9.06M)(58.58M)
Preferred Dividends -----
Net Income Available to Common (90M)(169.15M)(272.69M)(9.06M)(58.58M)
EPS (Basic) (3.99)(6.69)(9.61)(0.29)(1.87)
Basic Shares Outstanding 22.53M25.3M28.37M30.97M31.3M
EPS (Diluted) (3.99)(6.69)(9.61)(0.29)(1.87)
Diluted Shares Outstanding 22.53M25.3M28.37M30.97M31.3M
EBITDA (153.39M)(182.76M)(264.77M)(113.65M)(39.31M)
Copyright 2021 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Link to MarketWatch's Slice.